A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study).
AIMS To evaluate the long-term efficacy and safety of teneligliptin add-on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. MATERIALS AND METHODS In this randomised, double-blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n...